Ark Bio
Singapore
About Ark Bio
Ark is an end-to-end solution provider focused on cancer early detection. By harnessing advanced data science and proprietary miRNA detection technology, Ark develops non-invasive and cost-effective blood tests to detect early stage cancers before clinical symptoms appear. The company collaborates extensively with top medical research institutions globally and is spearheading Asia’s largest miRNA clinical studies targeting more than 50,000 participants. Ark is headquartered in Singapore, with R&D, manufacturing and clinical diagnostic operations in China and USA.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $40.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2018)
- Website: ark.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/ark-bio-28307 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.